Rory Shallis, MD

• Alexa Siddon
• Alexander B. Pine
• Amer Zeidan
• Darko Pucar
• Iris Isufi
• Jeanne Hendrickson
• Kenneth B. Roberts
• Lohith Gowda
• Manoj M Pillai
• Maricar Malinis
• Marwan Mikheal Azar
• Mina Xu
• Natalia Neparidze
• Nicole Deziel
• Nikolai Podoltsev
• Prajwal Boddu
• Rong Wang
• Samuel Katz
• Scott Huntington
• Shana Gleeson
• Smith Giri
• Stephanie Halene
• Stephanie Prozora
• Stuart Seropian
• Sudhir Perincheri
• Tae Kon Kim
• Terri Parker
• Thomas Prebet
• Wei Wei
• Xiaomei Ma
• Yuval Kluger

Epidemiology; Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases

• Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.Bewersdorf JP, Shallis RM, Zeidan AM. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews 2021, 45:100709.
• Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Current Opinion In Hematology 2021, 28:110-121.
• The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. Blood Reviews 2021, 48:100806.
• Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma, Myeloma & Leukemia 2021, 21:e483-e487.
• Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clinical Lymphoma, Myeloma & Leukemia 2021, 21:421-424.e2.
• Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Advances 2021, 5:994-1002.
• Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/oncology Clinics Of North America 2021, 35:177-189.
• The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia.Shallis RM, Boddu PC, Bewersdorf JP, Zeidan AM. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 2020, 40:100639.
• The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. Blood Reviews 2020, 43:100650.
• Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia.Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, Gore SD. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leukemia Research 2020, 90:106315.
• Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Cruz EA, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & Lymphoma 2020, 61:1220-1225.
• Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020, 34:3149-3160.
• Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes.Shallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review Of Hematology 2020, 13:447-460.
• Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits.Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13:489-499.
• Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma & Leukemia 2020, 20:556-560.e2.
• Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4:1615-1623.
• Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?Bewersdorf JP, Shallis RM, Diadamo A, Gowda L, Podoltsev NA, Siddon A, Zeidan AM. Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought? Leukemia & Lymphoma 2020, 61:2254-2257.
• Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leukemia & Lymphoma 2020, 61:2180-2190.
• Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4:2192-2201.
• Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances 2020, 4:2308-2316.
• Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?Shallis RM, Zeidan AM. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? Best Practice & Research. Clinical Haematology 2020, 33:101132.
• Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42:100706.
• Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet. Haematology 2020, 7:e601-e612.
• A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia.Shallis RM, Weiss JJ, Deziel NC, Gore SD. A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia. Blood Reviews 2021, 47:100736.
• Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst.Shallis RM, Weiss JJ, Deziel NC, Gore SD. Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. Blood Reviews 2021, 47:100760.
• Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2021, 47:100773.
• Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials.Shallis RM, Pollyea DA, Zeidan AM. Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. The Lancet. Haematology 2020, 7:853-856.
• Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer 2021, 127:1039-1048.
• High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.Zhao J, Bewersdorf JP, Jaszczur S, Kowalski A, Perreault S, Schiffer M, Gore S, Podoltsev N, Prebet T, Shallis R, Zeidan AM. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia & Lymphoma 2021, 62:1195-1202.
• Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2019, 34:1-15.
• Epigenetic therapy combinations in acute myeloid leukemia: what are the options?Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Therapeutic Advances In Hematology 2019, 10:2040620718816698.
• Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60:2584-2587.
• What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?Shallis RM, Podoltsev N. What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly? Expert Opinion On Pharmacotherapy 2019, 20:1169-1173.
• Getting personal with myelodysplastic syndromes: is now the right time?Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Review Of Hematology 2019, 12:215-224.
• Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36:70-87.
• Healthcare expenses for treatment of acute myeloid leukemia.Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12:641-650.
• Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review Of Anticancer Therapy 2019, 19:717-729.
• Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis.Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. Cancer 2019, 125:4241-4251.
• Changes in intestinal microbiota and their effects on allogeneic stem cell transplantation.Shallis RM, Terry CM, Lim SH. Changes in intestinal microbiota and their effects on allogeneic stem cell transplantation. American Journal Of Hematology 2018, 93:122-128.
• Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leukemia & Lymphoma 2018, 59:2015-2017.
• More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 2018, 18:4.
• Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11:715-726.
• Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts.Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European Journal Of Haematology 2018, 101:711-720.
• The genetic and molecular pathogenesis of myelodysplastic syndromes.Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal Of Haematology 2018, 101:260-271.
• Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies. Annals Of Hematology 2018, 97:2245-2248.
• Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice.Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97:2333-2343.
• Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review.Shallis RM, Rome RS, Reagan JL. Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review. Clinical Lymphoma, Myeloma & Leukemia 2018, 18:e123-e129.
• Day 14 bone marrow examination in the management of acute myeloid leukemia.Terry CM, Shallis RM, Estey E, Lim SH. Day 14 bone marrow examination in the management of acute myeloid leukemia. American Journal Of Hematology 2017, 92:1079-1084.
• The multi-faceted potential of CD38 antibody targeting in multiple myeloma.Shallis RM, Terry CM, Lim SH. The multi-faceted potential of CD38 antibody targeting in multiple myeloma. Cancer Immunology, Immunotherapy : CII 2017, 66:697-703.
• Tobacco Smoking as a Risk Factor for Increased Antibiotic Prescription.Steinberg MB, Akincigil A, Kim EJ, Shallis R, Delnevo CD. Tobacco Smoking as a Risk Factor for Increased Antibiotic Prescription. American Journal Of Preventive Medicine 2016, 50:692-698.
• Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.El Chaer F, Borate U, Duléry R, Holtan SG, Law AD, Muffly L, Nassereddine S, Shallis RM, Stringaris K, Taylor J, Devine SM, Mohty M, Hourigan CS. Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances 2021, 5:1757-1759.
• Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation 2021, 56:1998-2004.
• Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.Shallis RM, Siddon AJ, Zeidan AM. Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. Current Hematologic Malignancy Reports 2021, 16:276-285.
• Emerging agents and regimens for polycythemia vera and essential thrombocythemia.Shallis RM, Podoltsev NA. Emerging agents and regimens for polycythemia vera and essential thrombocythemia. Biomarker Research 2021, 9:40.
• Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies.Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021.
• Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes.Abel GA, Klepin HD, Magnavita ES, Jaung T, Lu W, Shallis RM, Hantel A, Bahl NE, Dellinger-Johnson R, Winer ES, Zeidan AM. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion 2021, 61:2830-2836.
• Management of the Older Patient with Myelodysplastic Syndrome.Shallis RM, Zeidan AM. Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging 2021, 38:751-767.
• Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Annals Of Hematology 2021.
• Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States.Bewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States. Blood Advances 2021.